A Service For Professionals Saturday, December 16, 2017
Contact (202) 540-8337
Breast Cancer News Today
A Service For Professionals Saturday, December 16, 2017 11610 Sources 421,630,082 Articles 2,875,095 Readers
Contact (202) 540-8337

Nonalcoholic Steatohepatitis (NASH) 2017 Market Insights, Epidemiology and Forecast – 2027

WiseGuyReports.com adds “Nonalcoholic Steatohepatitis (NASH) Market 2017 Global Analysis Research Report Forecasting to 2027”reports to its database.

PUNE, INDIA, November 8, 2017 /EINPresswire.com/ -- Nonalcoholic Steatohepatitis (NASH) Market:

Executive Summary

DelveInsight’s ‘Nonalcoholic Steatohepatitis (NASH)- Market Insights, Epidemiology and Market Forecast-2027’ report provides a disease overview of the Nonalcoholic Steatohepatitis (NASH) along with the epidemiology and the market scenario in the 7MM – United States, EU5 (Germany, France, Spain Italy , United Kingdom) and Japan.

The Report covers the therapeutics market revenue, treatment practice and Nonalcoholic Steatohepatitis (NASH) forecasted market share from 2017 to 2027 segmented by seven major markets. In addition, the report also includes global forecast of epidemiology of Nonalcoholic Steatohepatitis (NASH) till 2027. Our epidemiology forecast covers the prevalent population as well as the diagnosed population having Nonalcoholic Steatohepatitis (NASH).

The report also covers the detailed market size forecast for 7MM. According to DelveInsight, it is estimated that the market size of Nonalcoholic Steatohepatitis (NASH) in 7MM shall increase and reach up to 49.25 Billion in 2027, with the compound annual growth rate (CAGR) of 23.0% for the period i.e., 2015-2027.

Request Sample Report @ https://www.wiseguyreports.com/sample-request/2477598-nonalcoholic-steatohepatitis-nash-market-insights-epidemiology-and-market-forecast-2027

Nonalcoholic Steatohepatitis (NASH) is a subtype of NAFLD (Nonalcoholic Fatty Liver Disease) that is characterized by accumulation of large amount of fat in the liver, along with inflammation and scarring. NASH is one of the most common liver related health problem and is considered to be strongly associated with insulin resistance, central obesity, reduced glucose tolerance, type 2 diabetes mellitus (T2DM), arterial hypertension, and hypertriglyceridemia. The condition can further progress to cirrhosis, liver failure and rarely liver cancer.

Key Coverage and Benefits:

The report will help in developing business strategies by understanding the trends shaping and driving the global Nonalcoholic Steatohepatitis (NASH) market.
Organize sales and marketing efforts by identifying the best opportunities for Nonalcoholic Steatohepatitis (NASH) in US, European Union 5 (EU5- Germany, Spain, Italy, France and United Kingdom) and Japan.
To understand the future market competition in the global Nonalcoholic Steatohepatitis (NASH) market and Insightful review of the key market drivers and barriers.
To understand the regulatory scenario in major markets.

For further information on this report, visit - https://www.wiseguyreports.com/enquiry/2477598-nonalcoholic-steatohepatitis-nash-market-insights-epidemiology-and-market-forecast-2027

Table of Contents

1. Report Introduction 
2. Non-Alcoholic Steatohepatitis Market Overview at a Glance 
3. Total Market Share Distribution of Non-Alcoholic Steatohepatitis for 7 MM in 2016 
4. Total Market Share Distribution of Non-Alcoholic Steatohepatitis for 7 MM in 2027 
5. Non-Alcoholic Steatohepatitis 
    5.1. Introduction 
    5.2. Types 
    5.3. Classification of NASH: Stages of Fibrosis 
    5.4. Causes 
    5.5. Pathophysiology 
    5.6. Symptoms 
    5.7. Diagnosis 
6. Epidemiology and Patient Population 
7. Key Points: 
8. Population and Forecast Parameters 
9. Prevalent Population of NASH in 7MM 
10. Region-Wise Prevalent Population of NASH 
11. Diagnosed Population of NASH in 7MM 
12. Region-Wise Diagnosed Population of NASH 
13. Treatment Algorithm 
14. American Association for the Study of Liver Diseases (AASLD) Current Recommendations for NAFLD/NASH 
15. EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease 
16. Guideline for NAFLD/NASH, by the Japanese Society of Gastroenterology (JSG) in cooperation with “The Japan Society of Hepatology” 
17. Unmet Needs 
18. Emerging Drugs 
    18.1. Phase-III Drugs Analysis 
    18.2. Phase-II Drugs Analysis 
19. Emerging Therapies 
    19.1. Elafibranor(GFT505): GenfitPharma 
      19.1.1. Regulatory Milestones 
      19.1.2. Other development activities 
      19.1.3. Clinical Development 
      19.1.4. Ongoing Trials Information 
      19.1.5. Safety and Efficacy 
      19.1.6. Advantages and Disadvantages 
      19.1.7. Product Profile 
    19.2. Obeticholic Acid (OCA): Intercept Pharmaceuticals, Inc. 
      19.2.1. Regulatory milestones 
      19.2.2. Other development activities 
      19.2.3. Clinical Development 
      19.2.4. Ongoing Trials Information 
      19.2.5. Safety and Efficacy 
      19.2.6. Advantages and Disadvantages 
      19.2.7. Product Profile 
    19.3. Selonsertib (Ask-1 Inhibitor): Gilead Sciences, Inc. 
      19.3.1. Other development activities 
      19.3.2. Clinical Development 
      19.3.3. Clinical Pipeline Activity 
      19.3.4. Safety and Efficacy 
      19.3.5. Advantages and Disadvantages 
      19.3.6. Product Profile 
    19.4. Cenicriviroc (CVC): Allergan/Tobira Therapeutics 
      19.4.1. Regulatory milestones 
      19.4.2. Other development activities 
      19.4.3. Clinical Development 
      19.4.4. Ongoing Trials Information 
      19.4.5. Safety and Efficacy 
      19.4.6. Advantages and Disadvantages 
      19.4.7. Product Profile 
    19.5. NGM282: NGM Biopharmacueticals, Inc. 
      19.5.1. Other development activities 
      19.5.2. Clinical Development 
      19.5.3. Ongoing Trials Information 
      19.5.4. Safety and Efficacy 
      19.5.5. Advantages and Disadvantages 
      19.5.6. Product Profile 
    19.6. BMS-986036:Bristol-Myers Squibb Company 
      19.6.1. Other development activities 
      19.6.2. Clinical Development 
      19.6.3. Ongoing trials information 
      19.6.4. Safety and Efficacy 
      19.6.5. Advantages and Disadvantages 
      19.6.6. Product Profile 
    19.7. Emricasan: Conatus Pharmaceuticals Inc. 
      19.7.1. Regulatory milestones 
      19.7.2. Other development activities 
      19.7.3. Clinical Development 
      19.7.4. Ongoing trials information 
      19.7.5. Safety and Efficacy 
      19.7.6. Product Profile 
    19.8. IVA337: Inventiva Pharma 
      19.8.1. Regulatory milestones 
      19.8.2. Clinical Development 
      19.8.3. Ongoing trial information 
      19.8.4. Safety and Efficacy 
      19.8.5. Product Profile 
20. Nonalcoholic Steatohepatitis (NASH): Country-Wise Market Analysis 
21. United States 
22. Europe 
23. Germany 
24. France 
25. Italy 
26. Spain 
27. United Kingdom 
28. Japan 
29. Market Drivers 
30. Market Barriers 
31. Appendix 
32. Report Methodology 
33. Consulting Services    

Continuous…

Buy this Report @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=2477527

Norah Trent
WiseGuy Research Consultants Pvt. Ltd.
+1 646 845 9349 / +44 208 133 9349
email us here

Powered by EIN Presswire